2-amido-3-(1H-indol-3-yl)-N-substituted-propanamides as a new class of falcipain-2 inhibitors. 1. Design, synthesis, biological evaluation and binding model studies. 2009

Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, PR China. jinzh@mail.ecust.edu.cn

The Plasmodium falciparum cysteine protease falcipain-2 (FP-2) is an important cysteine protease and an essential hemoglobinase of erythrocytic P. falciparum trophozoites. The discovery of new FP-2 inhibitors is now a hot topic in the search for potential malaria treatments. In this study, a series of novel small molecule FP-2 inhibitors have been designed and synthesized based on three regional optimizations of the lead (R)-2-phenoxycarboxamido-3-(1H-indol-3-yl)-N-benzylpropanamide(1), which was identified using structure-based virtual screening in conjunction with surface plasmon resonance (SPR)-based binding assays. Four compounds--1, 2b, 2k and 2l--showed moderate FP-2 inhibition activity, with IC(50) values of 10.0-39.4 microM, and the inhibitory activity of compound 2k was approximately 3-fold better than that of the prototype compound 1 and may prove useful for the development of micromolar level FP-2 inhibitors. Preliminary SAR data was obtained, while molecular modeling revealed that introduction of H-bond donor or/and acceptor atoms to the phenyl ring moiety in the C region would be likely to produce some additional H-bond interactions, which should consequently enhance molecular bioactivity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
May 2016, Molecules (Basel, Switzerland),
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
May 2007, Bioorganic & medicinal chemistry,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
September 2014, Journal of medicinal chemistry,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
September 2017, European journal of medicinal chemistry,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
February 1999, Journal of medicinal chemistry,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
July 2017, Pakistan journal of pharmaceutical sciences,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
April 2005, The Journal of organic chemistry,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
December 2020, Journal of enzyme inhibition and medicinal chemistry,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
September 2019, ACS medicinal chemistry letters,
Jin Zhu, and Tong Chen, and Lili Chen, and Weiqiang Lu, and Peng Che, and Jin Huang, and Honglin Li, and Jian Li, and Hualiang Jiang
November 2011, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!